Fibroblast growth factor receptors as treatment targets in clinical oncology

M Katoh - Nature reviews Clinical oncology, 2019 - nature.com
FGFRs are receptor tyrosine kinases with a role in several biological processes, such as the
regulation of development and tissue repair. However, alterations in FGFRs 1–4, such as …

Inhibition of FGF‐FGFR and VEGF‐VEGFR signalling in cancer treatment

G Liu, T Chen, Z Ding, Y Wang, Y Wei, X Wei - Cell proliferation, 2021 - Wiley Online Library
The sites of targeted therapy are limited and need to be expanded. The FGF‐FGFR
signalling plays pivotal roles in the oncogenic process, and FGF/FGFR inhibitors are a …

The landscape of genomic alterations across childhood cancers

SN Gröbner, BC Worst, J Weischenfeldt, I Buchhalter… - Nature, 2018 - nature.com
Pan-cancer analyses that examine commonalities and differences among various cancer
types have emerged as a powerful way to obtain novel insights into cancer biology. Here we …

Clinical sequencing of soft tissue and bone sarcomas delineates diverse genomic landscapes and potential therapeutic targets

BA Nacev, F Sanchez-Vega, SA Smith… - Nature …, 2022 - nature.com
The genetic, biologic, and clinical heterogeneity of sarcomas poses a challenge for the
identification of therapeutic targets, clinical research, and advancing patient care. Because …

[HTML][HTML] FGFR inhibitors: Effects on cancer cells, tumor microenvironment and whole-body homeostasis

M Katoh - International journal of molecular medicine, 2016 - spandidos-publications.com
Abstract Fibroblast growth factor (FGF) 2, FGF4, FGF7 and FGF20 are representative
paracrine FGFs binding to heparan-sulfate proteoglycan and fibroblast growth factor …

New insights into the physiology and pathophysiology of the atypical sodium leak channel NALCN

A Monteil, NC Guérineau, A Gil-Nagel… - Physiological …, 2024 - journals.physiology.org
Cell excitability and its modulation by hormones and neurotransmitters involve the concerted
action of a large repertoire of membrane proteins, especially ion channels. Unique …

Schlafen 11 (SLFN11), a restriction factor for replicative stress induced by DNA-targeting anti-cancer therapies

J Murai, A Thomas, M Miettinen, Y Pommier - Pharmacology & therapeutics, 2019 - Elsevier
Abstract Schlafen 11 (SLFN11) sensitizes cells to a broad range of anti-cancer drugs
including platinum derivatives (cisplatin and carboplatin), inhibitors of topoisomerases …

Therapeutics targeting FGF signaling network in human diseases

M Katoh - Trends in pharmacological sciences, 2016 - cell.com
Fibroblast growth factor (FGF) signaling through its receptors, FGFR1, FGFR2, FGFR3, or
FGFR4, regulates cell fate, angiogenesis, immunity, and metabolism. Dysregulated FGF …

Future applications of FGF/FGFR inhibitors in cancer

GC Ghedini, R Ronca, M Presta… - Expert review of …, 2018 - Taylor & Francis
Introduction: Deregulation of the fibroblast growth factor (FGF)/FGF receptor (FGFR) network
occurs frequently in tumors due to gene amplification, activating mutations, and oncogenic …

A 2015 update on predictive molecular pathology and its role in targeted cancer therapy: a review focussing on clinical relevance

M Dietel, K Jöhrens, MV Laffert, M Hummel… - Cancer gene …, 2015 - nature.com
In April 2013 our group published a review on predictive molecular pathology in this journal.
Although only 2 years have passed many new facts and stimulating developments have …